Learns more about the ioverame dials branch treatments

Clinical Outcomes of Lumbar Facet Arthroplasty for Degenerative Lumbar Disease: A Systematic Review and Meta-Analysis of Predominantly Total Posterior Spine System Evidence

  • International Journal of Spine Surgery
  • October 2026,
  • 8968;
  • DOI: https://doi.org/10.14444/8968

Abstract

Background Lumbar facet joint arthroplasty has emerged as a motion-preserving alternative to fusion for the treatment of degenerative lumbar spine diseases. While early studies have reported promising outcomes, the overall clinical efficacy, durability, and safety profile remain incompletely defined.

Objective To systematically evaluate the clinical, radiographic, and perioperative outcomes of lumbar facet arthroplasty in patients with degenerative lumbar disease.

Methods A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Web of Science, and Scopus were searched through November 2025. Eligible studies included clinical investigations of posterior lumbar facet arthroplasty in degenerative conditions with a minimum sample size of 10 patients. Outcomes of interest included reoperation rates, patient-reported outcomes (visual analog scale [VAS], Oswestry Disability Index [ODI]), range of motion (ROM), and perioperative parameters. Random-effects meta-analysis was performed, and heterogeneity was assessed using I² statistics. Risk of bias was evaluated using the Joanna Briggs Institute’s critical appraisal tools.

Results A total of 13 reports were included, 11 of which supplied data for outcome-specific meta-analyses. The conversion to fusion or arthroplasty removal was 6% and 7%, respectively. Final leg and back VAS scores were 1.10 and 1.72, with mean changes of −6.36 and −5.36, respectively; the final ODI was 17.30 (Δ −37.52), and ROM was 6.40° (Δ −0.21°). The mean blood loss and operating time were 391.74 mL and 186.72 minutes. Adjacent-segment reoperation was observed in 0/206 arthroplasty and 5/93 fusion patients in 1 randomized Total Posterior Spine System (TOPS) comparison. Most outcomes were highly heterogeneous.

Conclusions Available evidence—predominantly for TOPS—suggests improvement in pain and disability with preservation of segmental motion. There was a high degree of heterogeneity; however, scanty comparative evidence and differences in follow-up make it difficult to draw conclusions and generalizations from the data across devices.

Clinical Relevance Lumbar facet arthroplasty may improve pain and disability while preserving motion in selected patients. Evidence is predominantly TOPS-based, and long-term durability and superiority to fusion remain uncertain.

Level of Evidence 4.

Introduction

Degenerative lumbar spine diseases represent a major source of disability worldwide, particularly in individuals older than 40 years, with an estimated prevalence ranging from 4% to 11%.1–3 Among these conditions, lumbar spinal stenosis and degenerative spondylolisthesis are the most common clinical entities, often presenting either independently or in combination and imposing a substantial clinical and socioeconomic burden.3

The traditional surgical management of these conditions has centered on decompression with or without fusion. While fusion procedures have demonstrated reliable efficacy in relieving symptoms and improving function,4,5 they are associated with several well-recognized drawbacks, including loss of segmental motion, adjacent segment degeneration/disease (ASD), and a measurable risk of reoperation.6,7

Lumbar facet joint arthroplasty has emerged as a posterior, motion-preserving strategy designed to maintain segmental stability following decompression while avoiding the biomechanical consequences of fusion. This technique involves replacement of the resected facet joints using prosthetic systems, most notably the Total Posterior Spine System (TOPS; Premia Spine), a pedicle screw-based construct that aims to restore near-physiologic motion while providing stability. Early clinical and randomized investigational device exemption (IDE) trials have demonstrated that facet arthroplasty can achieve outcomes comparable or superior to transforaminal lumbar interbody fusion (TLIF) in terms of disability, pain relief, and overall clinical success.1,4,5,8 Furthermore, cost-effectiveness analyses suggest that TOPS may offer greater quality-adjusted life years at similar or lower costs over short- to midterm follow-up.9 Other systems, such as the Total Facet Arthroplasty System (TFAS; Archus Orthopedics), have shown promising biomechanical performance in preclinical studies; however, clinical data remain limited and less conclusive.10

Despite these encouraging findings, concerns persist regarding implant-related complications, including pedicle screw loosening, hardware failure, and hypersensitivity reactions, which may offset potential benefits.4,11 Moreover, the current literature remains heterogeneous, with variations in study design, patient selection, implant type, and follow-up duration. To date, there is no comprehensive synthesis of the available clinical evidence that simultaneously evaluates both the efficacy and safety profile of lumbar facet arthroplasty.

Accordingly, the present systematic review and meta-analysis aimed to critically evaluate the existing clinical literature on lumbar facet joint arthroplasty in the management of degenerative lumbar diseases.

Methods

All steps of this systematic review followed the PRISMA guidelines.12 The review protocol was registered in PROSPERO (CRD420251265605).

Search Strategy and Eligibility Criteria

A comprehensive literature search was performed across PubMed, Embase, Web of Science, and Scopus from database inception through November 2025. The search strategy incorporated combinations of keywords and controlled vocabulary related to lumbar facet arthroplasty, degenerative spondylolisthesis, and spinal stenosis. The complete search strategy for each database is provided in Table S1 in the Supplemental Tables file.

Studies were considered eligible if they met the following criteria: (1) original clinical studies involving patients with degenerative lumbar spine disease; (2) use of posterior lumbar facet joint arthroplasty; (3) interventional study design (single-arm or comparative); and (4) a minimum sample size of 10 patients.

Exclusion criteria included (1) non-English language publications; (2) studies involving nondegenerative spinal pathologies; (3) studies evaluating arthroplasty techniques other than posterior facet arthroplasty; and (4) nonoriginal articles (eg, reviews, editorials, and conference abstracts).

Screening and Data Extraction

All identified records were imported into a reference management system, and duplicates were removed. Two independent reviewers screened titles and abstracts for eligibility. Full texts of potentially relevant studies were subsequently assessed for inclusion. Discrepancies between reviewers were resolved through discussion and consensus with a senior author.

Two reviewers independently collected the data on a standard form. Variables extracted comprised study design, number of patients, age, gender, body mass index (BMI), diagnosis, arthroplasty device, number of arthroplasty levels performed, US Food and Drug Administration (FDA) trial status, funding status, and eligibility criteria, including the presence of osteoporosis and BMI > 40 as well as the length of follow-up. We recorded whether each study was part of a US Food and Drug Administration Investigational Device Exemption (FDA IDE) trial (yes/no). This variable reflected trial participation, not device marketing approval. Outcomes reported were conversion to fusion, arthroplasty removal, back visual analog scale (VAS) scores, leg VAS scores, Oswestry Disability Index (ODI) scores, range of motion (ROM), blood loss, operative time, adjacent-segment outcomes, and device-specific complications. We also identified the methods used for the assessment of the ROM and the definition of blood loss and operating time.

Overlapping Studies

Reports from the same underlying cohort were linked. Nassr et al,3 Shaffer et al,7 Coric et al,6 and Pinter et al4 were treated as 1 TOPS IDE cohort; Anekstein et al13 and Smorgick et al5 as 1 longitudinal TOPS cohort; and Sielatycki et al14 and Sivaganesan15 as 1 lumbar total joint replacement (LTJR) cohort. Each independent cohort was only included in a single report for a particular quantitative result, and the report with the most complete information was used for that result.

Quality Evaluation

The methodological quality and risk of bias of included studies were evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools appropriate for each study design, including case series, cohort studies, quasi-experimental studies, and randomized controlled trials.16 Detailed assessment results are presented in Figures S1 to S3 (Supplemental Figures).

Statistical Analysis

Statistical analyses were conducted using R software (version 4.4.1) with the metafor, metasens, and metaplus packages. A random-effects model was applied to account for anticipated clinical and methodological heterogeneity across studies. Continuous outcomes (eg, VAS, ODI, ROM, operative time, and blood loss) were pooled as mean differences (MDs) with 95 % confidence intervals (CIs). Dichotomous outcomes (eg, reoperation rates, conversion to fusion, and arthroplasty removal) were pooled using logit-transformed proportions. Between-study heterogeneity was assessed using the I² statistic and τ², along with corresponding P values. Subgroup analyses included device type (TOPS, LTJR, TFAS, and ACADIA), FDA-trial status, funding, osteoporosis exclusion, BMI > 40 exclusion, and, when possible, follow-up duration (less than 24 months vs 24 months or longer). Anatomical definitions or failure mechanisms that were not equivalent were summarized on a narrative basis (instead of being pooled with outcomes) and included adjacent-segment and device-specific complications. Publication bias was evaluated using Egger’s regression test, with P < 0.05 considered indicative of potential small-study effects. In cases where publication bias was detected, the trim-and-fill method was applied as a sensitivity analysis to assess the robustness of pooled estimates. Forest plots for all pooled outcomes are provided in Figures S4–S15 in the Supplemental Figures file.

Results

Study Selection and Characteristics

A total of 1728 records were identified through database searches (PubMed, Embase, Web of Science, and Scopus). After removal of 381 duplicates, 1347 records underwent title and abstract screening. Of these, 1317 were excluded, leaving 30 reports for a full-text review. One report could not be retrieved, and 29 full-text articles were assessed for eligibility. During full-text evaluation, 14 conference abstracts and 2 cost-effectiveness studies were excluded. Thirteen reports were included in the qualitative synthesis, and 11 contributed to at least 1 quantitative outcome. Because several reports described overlapping cohorts, sample sizes were not summed as a unique-patient total (Figure).

Figure

PRISMA 2020 flow diagram illustrating the selection process for studies included in the systematic review.

The included studies comprised 4 clinical trials,3,4,6,7 2 retrospective cohort studies,14,15 and 7 case series.1,5,8,13,17–19 The mean patient age ranged from 53.1 to 67.8 years, and the mean BMI ranged from 28 to 29.7. The majority of patients were treated for single-level degenerative spondylolisthesis, lumbar spinal stenosis, or both. Most procedures were performed using the TOPS, although other devices, including LTJR, TFAS, and ACADIA, were also represented. Accordingly, the evidence base was mostly derived from TOPS, with more limited data for the other systems. Follow-up ranged from approximately 1.5 to 132 months, although most larger cohorts reported 12- to 24-month outcomes. Detailed baseline characteristics are summarized in Table 1.

View this table:
Table 1

Baseline characteristics of included lumbar facet arthroplasty reports.

Quality Appraisal and Risk of Bias

Quality assessment using JBI tools demonstrated generally moderate-to-high methodological quality across studies. Detailed assessments are provided in Figures S1–S3.

Reoperations and Device Survival

Pooled analysis of 4 studies including 259 patients demonstrated a conversion-to-fusion rate of 6 % (95% CI: 1%–29%), with substantial heterogeneity (I² = 70.9%, P = 0.016). Arthroplasty removal was observed in 7% of patients (95% CI: 2%–22%), with moderate heterogeneity (I² = 53.0%, P = 0.094) (Table 2). Subgroup analyses revealed that FDA trial status and exclusion of patients with BMI > 40 were associated with significantly lower conversion-to-fusion rates (P = 0.0006 for both). Similarly, arthroplasty removal rates were significantly influenced by FDA trial status (P = 0.0047), device type (P = 0.0158), and exclusion of BMI > 40 (P = 0.0047) (Table 3).

View this table:
Table 2

Pooled meta-analysis results.

View this table:
Table 3

Subgroup analyzes of pooled outcomes.

There were few and inconsistent reports of device-specific complications, and these were not pooled. Reported events included internal device locking, screw loosening or migration, implant subsidence, precautionary bearing exchange, and trauma-related crossbar fracture (Table 4).

View this table:
Table 4

Device-specific and hardware-related complications.

Adjacent-Segment Outcomes

Outcomes of adjacent segments were inconsistently defined and were not pooled. Within the randomized TOPS IDE cohort, symptomatic adjacent-level stenosis requiring reoperation did not occur in any of the 206 arthroplasty patients, compared with 5 of 93 fusion patients (0% vs 5.4%, P = 0.003), with 6 procedures being performed in the 5 fusion patients with adjacent-level stenosis. Nonequivalent symptoms and radiographs were reported, such as index-level degeneration, progression of adjacent preexisting disease, and degeneration at more distant levels (Table 5).

View this table:
Table 5

Adjacent-segment and related radiographic outcomes.

Clinical Outcomes (VAS, ODI)

The pooled mean leg VAS score at latest follow-up (4 studies, n = 146) was 1.10 (95% CI: 0.19–2.02), with high heterogeneity (I² = 91.6%, P < 0.001). The pooled mean change in VAS (3 studies) was −6.36 (95% CI: −8.54 to −4.17), also with substantial heterogeneity (I² = 74.2%, P = 0.021) (Table 2). Subgroup analysis showed that exclusion of osteoporosis significantly influenced final VAS scores (P = 0.0021), while device type significantly affected VAS improvement (P = 0.0068) (Table 3).

The pooled mean back VAS score at latest follow-up (5 studies) was 1.72 (95% CI: 0.91–2.53), with substantial heterogeneity (I² = 84.5%, P < 0.001). The pooled mean change in back VAS (5 studies) was −5.36 (95% CI: −6.49 to −4.24), with high heterogeneity (I² = 91.9%, P < 0.001) (Table 2). Final back VAS scores showed significant differences between device types (P < 0.0001), patients in FDA trials (P = 0.0331), and exclusion of those with BMI > 40 (P = 0.0331), while funding showed significant differences in the change in back VAS scores (P = 0.0268) (Table 3).

The pooled ODI score at latest follow-up (5 studies, n = 198) was 17.30 (95% CI: 5.33–29.27), with considerable heterogeneity (I² = 94.5%, P < 0.001). The pooled mean improvement in ODI was −37.52 (95% CI: −45.85 to −29.19), also demonstrating high heterogeneity (I² = 92.2%, P < 0.001) (Table 2). Subgroup analyses indicated that device type (P < 0.0001), FDA trial status (P < 0.0001), funding (P = 0.0034), and exclusion of BMI > 40 (P < 0.0001) significantly influenced ODI outcomes (Table 3)

Range of Motion

Dynamic flexion-extension radiographs were used to assess ROM which was supplemented by lateral-bending views in some cohorts (Table S2) using Cobb or other segmental angular methods; angular landmarks and reader procedures were incompletely reported in several cohorts. The pooled ROM at latest follow-up (5 studies, n = 160) was 6.40° (95% CI: 3.64–9.17), with high heterogeneity (I² = 92.3%, P < 0.001). Egger’s test suggested potential publication bias (P < 0.05); however, trim-and-fill analysis showed the robustness of pooled estimates.

The pooled change in ROM (4 studies) was −0.21 (95% CI: −1.18 to 0.76), with no significant heterogeneity (I² = 0.0%, P = 0.45) (Table 2). Subgroup analysis demonstrated a significant effect of FDA trial status on final ROM (P = 0.0017), while no significant moderators were identified for change in ROM (Table 3).

Perioperative Parameters (Blood Loss and Operative Time)

The pooled mean intraoperative blood loss (5 studies, n = 308) was 391.74 mL (95% CI: 145.69–637.79), with very high heterogeneity (I² = 97.4%, P < 0.001). The pooled operative time (7 studies, n = 314) was 186.72 min (95% CI: 121.11–252.33), also with substantial heterogeneity (I² = 97.9%, P < 0.001) (Table 2).

Subgroup analyses revealed that device type significantly influenced both blood loss (P < 0.001) and operative time (P < 0.001). Additionally, FDA trial status (P = 0.0118) and exclusion of BMI > 40 (P = 0.0141) significantly affected blood loss (Table 3).

Subgroup analyses of follow-up duration were possible only for blood loss and operative time and were not associated with significant differences (P = 0.288 for blood loss and P = 0.811 for operative time; Table 3). There were mostly indirect comparisons of devices and no comparisons should be used to rank the systems, especially as there was no reporting on definition of blood loss or operative time (Table S2).

Discussion

In the reports included, evidence of improved pain and disability and preservation of segmental motion after the procedure of lumbar facet arthroplasty was provided. However, the evidence was largely TOPS-based, and the majority of studies were noncomparative, and many pooled estimates were heterogeneous and had broad CIs. Therefore, the combined results are only to be regarded as descriptive summaries and should not be considered as the definitive estimate of treatment effect.

Reoperation, Durability, and Device-Related Complications

The pooled conversion-to-fusion rate (6%) and arthroplasty removal rate (7%) suggest an acceptable reoperation profile for a relatively novel technology. However, the observed heterogeneity indicates that these outcomes are not uniform across studies and are likely influenced by differences in patient selection, implant design, surgical technique, and study setting. Subgroup analyses demonstrated that FDA-regulated trials and stricter patient selection (eg, exclusion of BMI > 40) were associated with lower failure rates, underscoring the importance of indication discipline. The selection of patients should continue to be device-specific. Current FDA labeling contraindicates TOPS implantation in patients with BMI > 40 or a lumbar spine T-score <−2.0; these thresholds should not be generalized to other systems. For patients who are still eligible for the treatment of osteoporosis, a careful evaluation of bone health and optimization should be performed.6,14,17,20

Specific device complications were rare but varied among the different generations and designs, such as crossbar fracture due to trauma and internal component locking, screw loosening or migration, and subsidence (Table 4). No pooled hardware failure rate could be clinically interpreted, as there were different definitions of failure and some explantations were examples of degenerative progression rather than mechanical failure. The results should be interpreted in conjunction with the combined conversion-to-fusion and arthroplasty-removal rates.

The clinical wear was not specifically measured. The 6–48.5 mg of polycarbonate-urethane wear reported by the FDA in bench tests does not necessarily correlate with in-vivo years of device life, nor does it necessarily correlate with when clinically important wear occurs. Surveillance is continuing for 5 years after approval.20,21

Motion Preservation and Adjacent-Segment Outcomes

A key objective of facet arthroplasty is the preservation of segmental motion following decompression. The pooled ROM at follow-up (6.40°) supports the ability of these systems to maintain meaningful mobility. This finding is consistent with biomechanical and cadaveric studies demonstrating that facet arthroplasty systems can restore near-physiologic kinematics and maintain more natural load distribution compared to rigid fixation constructs.22–24 Importantly, the lack of significant change in ROM (ΔROM −0.21) suggests that motion is largely preserved rather than progressively lost over time. The absolute ROM values, however, should be viewed with some caution in view of the differences in the design of the implants, effort used by the patients, positioning, angular landmarks and the methods used by the readers between the different studies (Table S2).

Clinically significant adjacent-segment disease might be limited with preservation of motion. At 24 months, no patients in the TOPS group had adjacent-level stenosis that required reoperation and 5.4% in the fusion group had an adjacent-level stenosis that required reoperation (only randomized comparison).3 This potential early benefit is based on the first cohort and a relatively short follow-up, and the results of the observational analyses were too anatomically and clinically variable to combine. There have to be standardized long-term comparative reporting before highlighting the reduction in long-term adjacent-segment disease with facet arthroplasty.

Perioperative Considerations and Surgical Complexity

Facet arthroplasty is not minimally invasive; the procedures reported included posterior exposure, decompression, facet resection, and instrumented reconstruction, and there was no independent cohort examining a less-invasive approach, be it percutaneous or otherwise. This is reflected in the pooled blood loss (≈392 mL) and operative time (≈187 min) and accounts for the fact that it is difficult to compare due to the heterogeneity and unreported measurement definitions. The learning curve has not been quantified, and no proficiency threshold is available. FDA labeling requires experienced lumbar surgeons and hands-on device-specific training, while qualitative reports suggest improved efficiency and fewer early technical complications with experience and instrument refinement.1,4,14,25

Limitations

There are some limitations here that should be noted. The studies were not uniform in design, population, follow-up, or outcome measurement, and the ROM methods used were also different, and blood-loss and operative-time definitions were not reported. Because the definitions of adjacent segments were not equivalent, the denominators differed, and the types and frequency of events varied, no meta-analysis could be performed on the adjacent-segment outcomes; and no direct comparative adjacent-segment evidence was available from only 1 randomized study. Second, although randomized trials are emerging, a substantial portion of the evidence is derived from observational studies and case series, which are subject to selection bias and confounding. Third, follow-up duration varied considerably, limiting the ability to draw definitive conclusions regarding long-term implant durability and adjacent segment outcomes. Additionally, some studies included mixed pathologies or multi-level procedures, which may introduce further variability in outcomes and complicate interpretation. Finally, evidence of potential publication bias was identified for certain outcomes (eg, ROM), although sensitivity analyses suggested that the overall findings were robust.

Conclusion

The available evidence indicates that lumbar facet arthroplasty can be effective in reducing pain and disability with maintenance of motion at the level replaced, but evidence is mostly TOPS-related and is small in size and heterogeneous, with a high proportion of noncomparative studies. The 1 randomized TOPS cohort reported fewer adjacent-segment reoperations than fusion at 24 months; this result requires longer follow-up and independent validation. The current findings should therefore be considered hypothesis-generating and should not be interpreted as establishing broad equivalence or superiority to fusion across facet-arthroplasty systems.

Supplementary material

Supplemental Tables.

Supplemental Figures.

Footnotes

  • Funding The authors received no financial support for the research, authorship, and/or publication of this article.

  • Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. 1.
    ↵
    Knappe UJ , Reinecke D , Flörke M , Horn P , Schönmayr R . Facet joint replacement: intermediate- and long-term outcome in a large case series. J Neurol Surg A Cent Eur Neurosurg. 2021;82(1):34–42. 10.1055/s-0040-1716534
  2. 2.
    ↵
    Pateder DB , Benzel E . Noninstrumented facet fusion in patients undergoing lumbar laminectomy for degenerative spondylolisthesis. J Surg Orthop Adv. 2010;19(3):153–158.
  3. 3.
    ↵
    Nassr A , Coric D , Pinter ZW , et al . Lumbar facet arthroplasty versus fusion for grade-i degenerative spondylolisthesis with stenosis. J Bone Joint Surg Am. 2024;106(12):1041–1053. 10.2106/JBJS.23.00719
  4. 4.
    ↵
    Pinter ZW , Freedman BA , Nassr A , et al . A prospective study of lumbar facet arthroplasty in the treatment of degenerative spondylolisthesis and stenosis: results from the total posterior spine system (TOPS) IDE study. Clin Spine Surg. 2023;36(2):E59–E69. 10.1097/BSD.0000000000001365
  5. 5.
    ↵
    Smorgick Y , Mirovsky Y , Floman Y , Rand N , Millgram M , Anekstein Y . Long-term results for total lumbar facet joint replacement in the management of lumbar degenerative spondylolisthesis. J Neurosurg Spine. 2020;32(1):36–41. 10.3171/2019.7.SPINE19150
  6. 6.
    ↵
    Coric D , Nassr A , Kim PK , et al . Prospective, randomized controlled multicenter study of posterior lumbar facet arthroplasty for the treatment of spondylolisthesis. J Neurosurg Spine. 2023;38(1):115–125. 10.3171/2022.7.SPINE22536
  7. 7.
    ↵
    Shaffer A , Yu AK , Yu A , Huesmann G , Iyer R , Arnold PM . One- and 2-year outcomes of lumbar facet arthroplasty versus spinal fusion in young (<65 years) and old (≥65 years) patients for the treatment of degenerative spondylolisthesis and stenosis. N Am Spine Soc J. 2024;19:100329:100329. 10.1016/j.xnsj.2024.100329
  8. 8.
    ↵
    McAfee P , Khoo LT , Pimenta L , et al . Treatment of lumbar spinal stenosis with a total posterior arthroplasty prosthesis: implant description, surgical technique, and a prospective report on 29 patients. FOC. 2007;22(1):1–11. 10.3171/foc.2007.22.1.13
  9. 9.
    ↵
    Ament JD , Petros J , Zabehi T , Yee R , Johnson JP , Vokshoor A . A prospective study of lumbar facet arthroplasty in the treatment of degenerative spondylolisthesis and stenosis: cost-effective assessment from the total posterior spine system (TOPSTM) IDE study: 2-year model revision and sensitivity analyses based on 305 subjects. Spine J. 2024;24(6):1001–1014. 10.1016/j.spinee.2024.01.004
  10. 10.
    ↵
    Gu BJ , Blue R , Yoon J , Welch WC . Posterior lumbar facet replacement and arthroplasty. Neurosurg Clin N Am. 2021;32(4):521–526. 10.1016/j.nec.2021.05.011
  11. 11.
    ↵
    Palmer DK , Inceoglu S , Cheng WK . Stem fracture after total facet replacement in the lumbar spine: a report of two cases and review of the literature. Spine J. 2011;11(7):e15–9. 10.1016/j.spinee.2011.06.002
  12. 12.
    ↵
    Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/bmj.n71
  13. 13.
    ↵
    Anekstein Y , Floman Y , Smorgick Y , Rand N , Millgram M , Mirovsky Y . Seven years follow-up for total lumbar facet joint replacement (TOPS) in the management of lumbar spinal stenosis and degenerative spondylolisthesis. Eur Spine J. 2015;24(10):2306–2314. 10.1007/s00586-015-3850-0
  14. 14.
    ↵
    Sielatycki JA , Devin CJ , Pennings J , et al . A novel lumbar total joint replacement may be an improvement over fusion for degenerative lumbar conditions: a comparative analysis of patient-reported outcomes at one year. Spine J. 2021;21(5):829–840. 10.1016/j.spinee.2020.12.001
  15. 15.
    ↵
    Sivaganesan A , Koscielski M , Kabani AS , et al . 24-month patient-reported outcomes for a novel lumbar total joint replacement. N Am Spine Soc J. 2025;23:100747. 10.1016/j.xnsj.2025.100747
  16. 16.
    ↵
    Munn Z , Stone JC , Aromataris E , et al . Assessing the risk of bias of quantitative analytical studies: introducing the vision for critical appraisal within JBI systematic reviews. JBI Evid Synth. 2023;21(3):467–471. 10.11124/JBIES-22-00224
  17. 17.
    ↵
    Haleem S , Ahmed A , Ganesan S , McGillion SF , Fowler JL . Mean 5-year follow-up results of a facet replacement device in the treatment of lumbar spinal stenosis and degenerative spondylolisthesis. World Neurosurg. 2021;152:e645–e651. 10.1016/j.wneu.2021.06.045
  18. 18.
    ↵
    Vermesan D , Prejbeanu R , Daliborca CV , et al . A new device used in the restoration of kinematics after total facet arthroplasty. Med Devices (Auckl). 2014;7:157–163. 10.2147/MDER.S60945
  19. 19.
    ↵
    Lack W , Kutschera HP , Krugluger J . Mobility-maintaining facet arthroplasty of the lumbar spine with the second-generation TOPS system: a case series. Oper Neurosurg. 2022;23(1):14–21. 10.1227/ons.0000000000000226
  20. 20.
    ↵
    Summary of Safety and Effectiveness Data (SSED): TOPS™ System (U.S. Food and Drug Administration). 2023.
  21. 21.
    ↵
    Food US, Drug Administration . The TOPS System Continued F/U Study. P220002/PAS001. U.S. Food and Drug Administration. Updated 2026-08-02. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm?c_id=7492&t_id=756798.
  22. 22.
    ↵
    Zhu Q , Larson CR , Sjovold SG , et al . Biomechanical evaluation of the total facet arthroplasty system: 3-dimensional kinematics. Spine (Phila Pa 1976). 2007;32(1):55–62. 10.1097/01.brs.0000250983.91339.9f
  23. 23.
    ↵
    Phillips FM , Tzermiadianos MN , Voronov LI , et al . Effect of the total facet arthroplasty system after complete laminectomy-facetectomy on the biomechanics of implanted and adjacent segments. Spine J. 2009;9(1):96–102. 10.1016/j.spinee.2008.01.010
  24. 24.
    ↵
    Goel VK , Mehta A , Jangra J , et al . Anatomic facet replacement system (AFRS) restoration of lumbar segment mechanics to intact: a finite element study and in vitro cadaver investigation. SAS J. 2007;1(1):46–54. 10.1016/SASJ-2006-0010-RR
  25. 25.
    ↵
    Food US, Administration D. Premarket Approval Order: TOPS™ System (P220002). 2023. June 15. 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220002A.pdf.
View Abstract
Loading
Loading

ISASS27 Annual Conference at Loews Miami Beach Hotel, April 23-25, 2027